Neuromuscular Section
The Neuromuscular Section furthers patient care, research, and teaching in the area of neuromuscular disease.
|
Anthony A. Amato, MDChair |
Nate KosherAdministrator, Sciencenkosher@aan.com (612) 928-6088 |
The Neuromuscular Section furthers patient care, research, and teaching in the area of neuromuscular disease.
|
Anthony A. Amato, MDChair |
Nate KosherAdministrator, Sciencenkosher@aan.com (612) 928-6088 |
The Academy's Neurology Career Center is working to bring experienced members together with members who seek guidance on their career path. (August 24, 2012)
The National Amyotrophic Lateral Sclerosis (ALS) Registry is a groundbreaking effort in the fight against ALS. (June 20, 2012)
The AAN published a new guideline on plasmapheresis in neurologic disorders in the January 18, 2011, issue of Neurology®. (April 5, 2011)
On behalf of the Neuromuscular Section Committee I would like to thank those of you who attended the Section Meeting and the Neuromuscular Highlights in the Field presentation on Thursday, April 13, 2011 during the AAN Annual Meeting in Hawaii. (April 5, 2011)
The AAN has developed quality measures for the care of patients with Parkinson's disease. Designed to measure and improve the quality of care that is provided, these measures—the first developed solely by the AAN—were published in the November 30, 2010, edition of Neurology®. (April 5, 2011)
A new evidence-based clinical guideline published by the AAN in the March 16, 2010, edition of the journal Neurology® urges people with Parkinson's disease, their physicians, and caregivers to be aware of symptoms unrelated to movement. (April 5, 2011)
A new guideline from the American Academy of Neurology recommends that the drug quinine, although effective, should be avoided for treatment of routine muscle cramps due to uncommon but serious side effects. The guideline is published in the February 23, 2010, issue of Neurology®. (April 5, 2011)
Guidelines from the American Academy of Neurology identify the most effective treatments for amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease). (April 5, 2011)
Clinical Trials in Neuropathy, Clinical Trials in ALS, Clinical Trials in Myasthenia Gravis, and Clinical Trials in Myopathy (April 5, 2011)
Read the announcement and a related interview (April 5, 2011)
A guideline from the AAN finds children with microcephaly are at risk of neurologic and cognitive problems and should be screened for these problems. (April 5, 2011)
Information current as of 5/31/2011. Be advised to verify with the organization. The AAN is not responsible for incorrect information. (April 5, 2011)
